Esophageal Motility Disease Screening in Patient With Suspicion or Diagnosis of IBD

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02478944

Acronym

EMSIBD

Enrollment

Registered

2015-06-23

Start date

2014-10-31

Completion date

2017-01-31

Last updated

2016-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Keywords

Inflammatory bowel disease, Manometry

Brief summary

Aims: Prospective evaluation of patients with a suspicion or diagnosis of Inflammatory bowel disease (IBD) to evaluate osophageal motility before and during therapy Material and methods: The investigators prospectively perform manometry in patients with or with symptoms consistent with IBD. The investigators evaluate esophageal motility with high resolution manometry before, during and after IBD therapy. Clinical data are also collected to find possible correlations. The study do not modify the planned IBD therapy, but observe motility findings.

Detailed description

Oesophageal motility is measured with the high resolution manometry in order to detect pathologic peristaltic amplitude values among patient before and after therapy (mesalazine, steroids, biologicals) compared to the standard values detected among the normal population. Diagnosic intervention like oesophagoduodenoscopy, colonoscopy and stenosis ballon dilation are allowed as are part of the IBD therapy and follow up. No other interventions are administered to participants during this study.

Interventions

DEVICEManometry

Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Inflammatory bowel disease * Suspicion of inflammatory bowel disease

Exclusion criteria

* Pregnancy

Design outcomes

Primary

Measure	Time frame
Manometry finding (peristaltic amplitude values mmHG) compared to normal population findings	1 year
Correlation with gastrointestinal symptoms to manometry findings (peristaltic amplitude values)	1 year

Secondary

Measure	Time frame
Manometry findings (peristaltic amplitude values, mmHG) during therapy	1 year

Countries

Germany

Contacts

Primary ContactFrancesco Vitali, MD

francesco.vitali@uk-erlangen.de

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026